Posts in category Healthcare


H.C. Wainwright Slashes Price Target for Tetraphase Pharmaceuticals Inc (TTPH); Here’s Why

H.C. Wainwright’s Ed Arce reduces his price target on TTPH stock, anticipating the company’s UTI program has met its end.

Spooked Investors Send Galmed Pharmaceuticals Ltd (GLMD) Stock Spiraling; Maxim Weighs in

Did an iceberg just wallop into Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock? This biotech company’s shares …

Dane Leone Fears Regeneron Pharmaceuticals Inc Could Be Facing Big Competition from Roche

After Roche released initially reassuring datasets for its wet AMD and DME candidate, BTIG’s Dane Leone believes this spells trouble for REGN.

Catalyst Biosciences Inc: This Analyst Even More Confident in Hemophilia B Asset Following Encouraging Phase II Data

FBR’s George Zavoico looks ahead to CBIO’s next pivotal trial, bullish on CB 269d’s ability to lead to stable FIX activity into the mild hemophilia range.

Pieris Pharmaceuticals Inc: Third Deal in 13 Months Expands Anticalin Platform’s Ability to Market

H.C. Wainwright’s Joseph Pantginis serves up an upbeat take on a platform that is the fuel of all of PIRS’s current and future pipeline candidates.

Canaccord Sees Over 500% Upside For Palatin Technologies, Inc. (PTN)

Canaccord analyst John Newman is out with a bullish note on shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN), …

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Risky Fundamentals Likely To Just Get Worse This Year

BTIG’s Tim Chiang is out with a bearish case against Teva after last week’s less-than-stellar 2018 guidance reveal.

Analyst Derek Archila Sizes Up Risks to Teva Pharmaceutical Industries Ltd (ADR) Shares

As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.

Aurinia Pharmaceuticals Inc (AUPH) Is an Attractive Opportunity with 75% Upside

Aurinia potentially has the 1st treatment for lupus nephritis, says RBC Capital’s Douglas Miehm.

Gilead Sciences’ HIV Franchise Is Poised to Recapture Share, Says Senior Analyst Phil Nadeau

Gilead Sciences, Inc. (NASDAQ:GILD), which built its reputation on turning HIV drug cocktails into easy-to-use, daily, …